ClinicalTrials.gg
CompletedNCT00674453LACEUpdated Aug 10, 2011

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

A Phase 2 interventional study of Lasofoxifene and Placebo in Bone Loss, sponsored by Ligand Pharmaceuticals. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-08-10.

Primary conditionOsteoporosisRegistry: Bone Diseases, MetabolicReclassifiedWhy we changed it
Registry
Bone Diseases, Metabolic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis
Why
  1. The study's title name Osteoporosis, a narrower term within Bone Diseases, Metabolic.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ligand Pharmaceuticals · Phase 2, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Osteoporosis with a site in United Kingdom — 8 open to participants now, 9 under way, none of them phase 3. Osteoporosis · United Kingdom.

Enrollment
23rd of 35
51 · median 110
Started
2004
with 1 other
Phase 2
4 of 57
none open now
Registered
16th of 57
by date
Lead sponsor
2 of 57
Ligand Pharmaceuticals

Among the 57 studies in Osteoporosis with a site in United Kingdom, this one is the 23rd largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2004, is one of 4 in phase 2, and was the 16th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 57 studies in Osteoporosis with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Osteoporosis with a site in United Kingdom, or all of them as a file.
02

Study summary

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

03

Conditions studied

  • Bone Loss

Browse trials for

Keywords

  • Osteoporosis
  • lasofoxifene
  • bone density
  • bone markers
04

In context

Osteoporosis Reclassified

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

This study's enrollment of 51 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Ligand Pharmaceuticals is the lead sponsor of 21 studies on the registry; none are open to participants now.

Compared within Osteoporosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Bone Diseases, Metabolic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women over 50 years who have low bone mineral density.

Exclusion criteria

Exclusion Criteria:

  • Women who are under 50 years of age, are premenopausal, or who currently have osteoporosis are excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Lasofoxifene 0.25 mg/d

    Drug: Lasofoxifene

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Oral tablet, 0.25 mg, daily, 2 years

  • OtherPlacebo

    Matching placebo tablet given once daily for 2 years

07

What researchers measure

Primary outcomes

  1. Change in bone mineral density of the lumbar spine.

    Time frame: 2 years

Secondary outcomes

  1. The secondary outcomes are the levels of cells and proteins in the blood that provide information about the health of bone, along with change in bone mineral density of the hip and forearm.

    Time frame: 2 years

08

Study locations

1 site
  • Pfizer Investigational Site
    Sheffield, S5 7AU, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2008
First posted
May 7, 2008
Start
Sep 2004
CompletionActual
Sep 2007
Last update
Aug 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00674453
First posted
May 7, 2008
Start date
Sep 2004
Completion
Sep 2007
Last update
Aug 10, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasofoxifene

Start the discussion